Call goes out for papers on promising practical work with AI in drug discovery

A peer-reviewed journal has put out a call for papers to publish in an upcoming special issue on cutting-edge uses of AI in early-phase drug development.

The Journal of Medicinal Chemistry announced its project May 23.

Guest editors for the issue will include Steven Kearnes, PhD, of Google Research, and Jürgen Bajorath, PhD, of the University of Bonn in Germany.

The project leaders say they’ll consider a wide range of methods, applications and novel concepts but will look to emphasize by their choices “how AI approaches are already impacting drug discovery at present rather than how they might add value in the future.”

They’re especially interested in practical applications, case studies and industry-academia collaborations.

The submission period is open already and will remain so through December for articles, briefs and drug annotations. Opinion pieces need to be entered by the end of November.

The issue is slated for publication in June 2020.

For the full submission guidelines, click here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup